a breakthrough in rd for neglected diseases new ways to get the drugs we need研发的突破被忽视疾病的新方法得到我们需要的药物.pdfVIP

Open access, freely available online Neglected Diseases A Breakthrough in RD for Neglected Diseases: New Ways to Get the Drugs We Need Mary Moran esearch suggests that long-held beliefs on neglected- disease drug development activity are no longer Raccurate, and that these inaccurate beliefs have led—and are leading—to poorly designed and targeted government policies and incentives. On a more positive note, this research also highlights opportunities for better-targeted government policies that will more closely match the reality of neglected-disease drug development and the needs of public and industry groups. Current Perceptions Current government policies to stimulate development of new drugs for neglected diseases are based on a set of shared understandings. One of these understandings is that only 13 new drugs have DOI: 10.1371/journal.pmed.0020302.g001 been developed for neglected tropical diseases since 1975, with the main problem being that these diseases are simply Figure 1. Active Neglected-Disease Drug Projects by Institution* non-commercial for companies to invest in [1]. Another is (Dec 2004) DNDi, Drugs for Neglected Diseases Initiative; IOWH, Institute for that, although public-private partnerships (PPPs) for drug OneWorld Health; MMV, Medicines for Malaria Venture; ND, neglected development have started, they are problematic. (In this diseases. article, PPPs are defi ned as public-health-driven not-for-profi t organisations that drive neglected-disease drug development in is generally based on supplementing low developing country conjunction with industry groups.) Governments are uncertai